ArticleBMC infectious diseases2025
Predictive and interpretable machine learning for COVID-19 resurgences: the role of SARS-CoV-2 variants in the post-pandemic era.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional COVID-19 forecasting often misses the rapid dynamics of viral competition, limiting timely ublic health responses. This study demonstrates the value of incorporating SARS-CoV-2 variant data into recurrent neural networks, using an interpretable, data-driven approach to improve accuracy in the current pandemic phase.
methodsWe validated our approach on post-pandemic data (2022–2025) from New York City and the United Kingdom, integrating epidemiological time series with genomic surveillance of variants. We implemented and compared several neural network structures, with LSTM achieving the best performance. To assess the contribution of variant-specific data, we compared models with and without variant inputs. For interpretability and understanding model decisions, we applied XAI techniques to quantify variant influence on predictions.
resultsIncorporating variant data markedly improved forecasting accuracy across all horizons. In New York City, MAPE dropped from 32.15% to 7.35% during periods of rapid variant change, while in the UK it fell from 35.62% to 7.73%. XAI analyses revealed the dominant role of specific variants and captured their competitive displacement dynamics, with model explanations closely matching observed epidemiological trends.
conclusionThis study introduces a variant-aware methodology that improves COVID-19 prediction in the current endemic phase. The main contributions are: (i) ablation studies demonstrating the value of incorporating variant data to model case resurgences and declines; (ii) interpretable results into variant-driven dynamics via XAI; and (iii) validation across multiple geographical scales. Our approach establishes a scalable paradigm for genomic-informed epidemic forecasting, adaptable to evolving respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.